Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
24 studies found for:    tas-102
Show Display Options
Rank Status Study
1 Recruiting A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC
Condition: Refractory Metastatic Colorectal Cancer
Interventions: Drug: TAS-102;   Drug: nivolumab
2 Recruiting Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer
Condition: Metastatic Colorectal Cancer
Intervention: Drug: TAS-102 and Bevacizumab
3 Recruiting Tas-102 and Radioembolization With 90Y Resin Microspheres for Chemo-refractory Colorectal Liver Metastases
Conditions: Colon Cancer;   Rectal Cancer;   Liver Metastases
Interventions: Drug: Tas-102;   Device: SIR-Sphere
4 Not yet recruiting TAS-102 in Previously Treated Unresectable or Metastatic Squamous Cell Lung Carcinoma (UF-STO-LUNG-003)
Condition: Squamous Cell Lung Carcinoma
Intervention: Drug: TAS-102
5 Active, not recruiting A Phase I/II Study for the Safety and Efficacy of Panitumumab in Combination With TAS-102 for Patients With Colorectal Cancer
Condition: Colorectal Cancer
Intervention: Drug: panitumumab, TAS-102
6 Not yet recruiting TAS-102 (Lonsurf) in Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma Post First Line Chemotherapy (UF-STO-PANC-003)
Condition: Pancreatic Cancer
Intervention: Drug: TAS-102
7 Completed Study Comparing the Bioavailability of TAS-102 Tablets to an Oral Solution Containing Equivalent Amounts of FTD and TPI
Condition: Advanced Solid Tumors (Excluding Breast Cancer)
Interventions: Drug: TAS-102 tablets;   Drug: TAS-102 oral solution
8 Recruiting Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer
Condition: Refractory Metastatic Gastric Cancer
Interventions: Drug: TAS-102;   Drug: Placebo
9 Completed A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Hepatic Impairment
Condition: Advanced Solid Tumors
Intervention: Drug: TAS-102
10 Not yet recruiting Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs
Conditions: Neuroendocrine Tumors;   Neoplasms;   Cancer;   Tumors
Interventions: Drug: TAS-102;   Drug: Temozolomide
11 Recruiting A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment
Condition: Advanced Solid Tumors
Intervention: Drug: TAS-102
12 Active, not recruiting A Phase I Study of TAS-102 in Solid Tumors
Condition: Advanced or Metastatic Solid Tumors
Intervention: Drug: TAS-102
13 Active, not recruiting Study of the Mass Balance of Oral FTD and TPI as Components of TAS-102 in Patients With Advanced Solid Tumors
Condition: Advanced Solid Tumors
Interventions: Drug: TAS-102 with a light tracer dose of [14C]FTD;   Drug: TAS-102 with a light tracer dose of [14C] TPI;   Drug: TAS-102 tablets
14 Recruiting Phase I Study of SGI-110 With Irinotecan Followed by Randomized Phase II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Previously Treated Metastatic Colorectal Cancer
Condition: Previously Treated Metastatic Colorectal Cancer
Interventions: Drug: SGI-110;   Drug: Irinotecan;   Drug: regorafenib;   Drug: TAS-102
15 Completed Study to Evaluate the Cardiac Safety of TAS-102 in Patients With Advanced Solid Tumors
Condition: Advanced Solid Tumors (Excluding Breast Cancer)
Interventions: Drug: TAS-102;   Drug: Placebo
16 Active, not recruiting A Phase I Study of TAS-102 in Patients With Advanced Gastrointestinal Tumors.
Condition: Advanced Gastrointestinal Tumors
Interventions: Drug: TAS-102;   Drug: CPT-11;   Drug: Bevacizumab
17 Active, not recruiting Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Condition: Colorectal Cancer
Interventions: Drug: TAS-102;   Drug: Placebo
18 Active, not recruiting Study Comparing the Pharmacokinetics of FTD as a Component of TAS-102 With FTD Alone
Condition: Advanced Solid Tumors
Interventions: Drug: TAS-102;   Drug: Trifluridine
19 Active, not recruiting Study of TAS-102 in Patients With Metastatic Colorectal Cancer in Asia
Condition: Colorectal Cancer
Interventions: Drug: TAS-102;   Drug: Placebo
20 Approved for marketing Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal Cancer
Condition: Colorectal Cancer Metastatic
Intervention: Drug: TAS-102

   Previous Page Studies Shown (1-20) Next Page (21-24) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.